Dipeptidyl Peptidase 4 Inhibitor

PreclinicalSmall molecule

Dipeptidyl Peptidase 4 Inhibitor is one of 114 small molecule programs targeting Cardiovascular Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

StrokeActive, not recruiting

Insulin SecretionActive, not recruiting

GLP-1Unknown status

Cardiovascular DiseasePreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

GLP-1Preclinical

Unknown status

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Nono-42

NNoNO Inc.

Phase 3

1 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Repatha

Proamatine

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Anticoagulant

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular Disease1 trial

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Completed·MMayo Clinic··NCT05214573·386,301 enrolled

Cardiovascular1 trial

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

Recruiting·—··NCT06301191·50 enrolled

MPA1 trial

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Completed·—·Phase 4·NCT03983551·101 enrolled

Short Bowel Syndrome1 trial

The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Terminated·SStanley Dudrick's Memorial Hospital·Phase 4·NCT02653131·8 enrolled

GLP-11 trial

Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01176760·30 enrolled

4 more indications

Non-Alcoholic Steatohepatitis1 trial

Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes

Completed·—·Phase 3·NCT06348706·60 enrolled

Treatment1 trial

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03807440·4,083 enrolled

Insulin Secretion1 trial

Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01176708·30 enrolled

Stroke1 trial

Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Unknown status·—··NCT05817097·22,119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Dipeptidyl Peptidase 4 Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dipeptidyl Peptidase 4 Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dipeptidyl Peptidase 4 Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Dipeptidyl Peptidase 4 Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiovascular Disease1 trial

Cardiovascular1 trial

MPA1 trial

Short Bowel Syndrome1 trial

GLP-11 trial

Non-Alcoholic Steatohepatitis1 trial

Treatment1 trial

Insulin Secretion1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News